• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Composition in micrometric size and its use as an adjuvant agent for plant alkaloids. Composition in micrometer size, its synthesis procedure and its use as an adjuvant agent for use together with pharmacologically active plant alkaloids in different pathologies, preferably prostate cancer, where the composition in micrometric size comprises: - at least one metal oxide preferably selected from oxides of magnesium, iron, molybdenum, zinc, aluminum, selenium and a mixture thereof, - at least one natural or synthetic polymer, or a combination of both, selected from: cellulose, agarose, polystyrene, polyvinyl alcohol (PVOH), and polyvinylidene fluoride (PVDF) and - at least one stabilizer selected from polyethylene glycol (PEG), polyethyleneimine (PEI), polyacrylic acid and isopropylacrylamine, preferably polyethylene glycol. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2823927A1
    申请号:ES201930977
    申请日:2019-11-07
    公开日:2021-05-10
    发明作者:Martínez Francisco Carlos Pérez；Fan Yang；Tao Wu
    申请人:Beijing Enbiwo Biological Tech Co Ltd；
    IPC主号:
    专利说明:

    [0002] Composition in micrometer size and its use as an adjuvant agent for plant alkaloids
    [0004] Field of the invention
    [0006] The present invention relates to a composition in micrometer size comprising at least one metal oxide combined with a polymer such as, for example, cellulose, and a stabilizer, such as polyethylene glycol (PEG), and its use for the preparation of an agent that potentiates the effect of a pharmacologically active molecule, such as a plant alkaloid, with which the material of the invention is co-administered, for the treatment of diseases.
    [0008] State of the art
    [0010] Docetaxel is classified as a "plant alkaloid", "taxane" and "antimicrotubular agent", and stands out for having significant antineoplastic and cytotoxic effects. Its synthesis is produced from the bark of the Pacific yew tree ( Taxus), like other taxanes.
    [0012] This plant alkaloid is approved for the treatment of breast cancer, non-small cell lung cancer, advanced stomach cancer, and metastatic prostate cancer. In this sense, prostate cancer is one of the most common cancers among men worldwide. It is a heterogeneous tumor with a slow but constant growth rate, which evolves from a localized stage with sensitivity to androgens to an advanced stage in which this sensitivity is lost.
    [0014] Treatment depends on the stage of the disease, if it is discovered early, it can be successfully treated by different procedures. However, when tumor cells become undifferentiated and evolve into a metastatic phenotype, current treatments offer less chance of cure.
    [0016] Tumors are characterized by cell division, which is no longer controlled as in normal tissue. "Normal" cells stop dividing when they come into contact with similar cells, a mechanism known as contact inhibition, which is lost in tumor cells. In tumor cells, the self-regulatory system that controls and limits cell division is unbalanced. The process of cell division, whether in normal or tumor cells, takes place through the cell cycle. This cycle goes from the resting phase, through the phases of active growth, to mitosis (division).
    [0017] The ability of chemotherapy to kill tumor cells depends on its ability to stop cell division. Usually, drugs work by damaging the RNA or DNA that tells the cell how to make a copy of itself in division. If the cells can not divide, they die. The faster the cells divide, the more likely the chemotherapy will kill the cells and the tumor will shrink. Furthermore, these drugs induce cell suicide (programmed cell death or apoptosis).
    [0019] Chemotherapy is very effective in killing rapidly dividing cells. Unfortunately, chemotherapy does not recognize the difference between tumor cells and "normal" cells in the body. The "normal" cells will grow back and be healthy, but in the meantime there are side effects. The "normal" cells most often affected by chemotherapy are blood cells, those found in the mouth, stomach, and intestines, as well as hair follicles; leading to low blood counts, mouth conditions, nausea, diarrhea, and / or hair loss.
    [0021] Today a multitude of chemotherapy drugs are used to treat tumors, either alone or in combination with other drugs or treatments. These drugs are very different in their chemical makeup, the way they are given, their usefulness in treating specific forms of certain tumors, and their side effects.
    [0023] In medicine, adjuvant treatment is called that which contributes or helps to solve the problem or disease, in a supplementary way. Its administration enhances the effect of the main treatment, allowing it to reduce its doses, reducing tolerance, toxicity and collateral effects. At present, most of the adjuvant drugs used together with chemotherapy are used to alleviate the side effects that these produce.
    [0025] The present invention refers to the reduction of these side effects through the reduction of the effective dose of the pharmacologically active plant alkaloid used, among other pathologies, in the treatment of tumors by using a composition in micrometer size that acts as an adjuvant.
    [0027] In addition to an advantage in increasing the efficacy of plant alkaloid treatments, the present invention also reduces the cost of treatment, contrary to what that is proposed with other effective and less toxic alternatives that are currently being developed.
    [0029] The use of a compound comprising polyethylene glycol for the treatment of colorectal cancer, ES2401269B1, is known, but the rest of the components differ from that of the present invention. In this sense, document ES2677242B1 refers to the formation of nanoconjugate compounds that have antitumor activity against advanced prostate cancer, but do not have similarity with the material used in the present invention.
    [0031] The present invention solves in a more efficient way than the current state of the art, different pathologies such as prostate cancer, since the composition of the invention enhances the effect of drugs acting as an adjuvant together with pharmacologically active plant alkaloids, among the which include, among others, docetaxel, paclitaxel or cabazitaxel.
    [0033] Some of the advantages of the composition of the present invention are the following: a) ease of preparation and reproducibility of the synthesis procedure; b) they are generally safe in vivo and not very toxic; and c) do not elicit a specific immune response and, therefore, can be administered repeatedly.
    [0035] Description of the invention
    [0037] The term "micrometric" as used herein refers to a material whose particles have all three dimensions in the order of the microscale, where the microscale is the range of about 1-100 pm.
    [0039] The term "pharmacologically active plant alkaloid" as used herein refers to a nitrogenous plant secondary metabolite that comes from the metabolic process of one or more amino acids and that generates physiological effects of different kinds.
    [0041] The term "biological fluids" refers to any organic fluid whatever, preferably, blood or blood plasma.
    [0043] The term "Aqueous Solvent" as used herein means water or any mixture of water with another water-miscible liquid.
    [0045] Any other term used herein will have the usual meaning in the field of art to which the present invention relates.
    [0046] The present invention relates to a composition in micrometer size comprising:
    [0047] - at least one metal oxide, preferably selected from oxides of: magnesium, iron, molybdenum, zinc, aluminum, selenium or a mixture thereof,
    [0049] - at least one natural or synthetic polymer, or a combination of both and
    [0051] - at least one stabilizer.
    [0053] The polymer can be a natural polymer, preferably cellulose or agarose.
    [0055] The polymer can be a synthetic polymer such as polystyrene, polyvinyl alcohol (PVOH), or polyvinylidene fluoride (PVDF).
    [0057] The stabilizer can be selected from polyethylene glycol (PEG), polyethyleneimine (PEI), polyacrylic acid and isopropylacrylamine.
    [0059] The metal oxides can be present in the form of microparticles with a diameter between 1 pm and 10 pm.
    [0061] The dimensions of the particles of the composition to which the present invention refers are between 1-100 pm, both sizes included.
    [0063] In a particular embodiment of the invention, the composition in micrometer size comprises a mixture of metal oxides, cellulose and polyethylene glycol (PEG). Preferred metal oxides are one or more compounds selected from: magnesium oxide (MgO), selenium dioxide (SeO2), iron (II) oxide (FeO), molybdenum trioxide (MoO 3 ), zinc oxide (ZnO) and Aluminum oxide (M 2 O 3 ).
    [0065] An additional object of the invention is the process of synthesis of the composition of the invention that comprises the following steps:
    [0067] (a) dissolve at least one metal oxide in a solvent to achieve a concentration of 4 5 g of each oxide per 100 ml of the solvent,
    [0069] (b) add to the solution from step (a) between 300 and 400 mg of each polymer for every 100 ml of the solution from step (a),
    [0071] (c) add to the solution from step (b) between 40 and 50 mg of each stabilizer for every 100 ml of the solution from step (b) and
    [0072] (d) sonicate the solution.
    [0074] According to a particular embodiment, the procedure comprises:
    [0076] (a) Dissolve at least one metal oxide in an aqueous solvent, preferably water to achieve a concentration of 4-5 g of each oxide per 100 ml of the aqueous solvent, preferably water, and stir for a time interval between 10-60 minutes, preferably 30 minutes,
    [0078] (b) add to the solution from step (a) between 300 and 400 mg of each polymer for every 100 ml of the solution from step (a) and continue stirring for a time interval between 10-60 minutes, preferably 30 minutes,
    [0080] (c) add to the solution from step (b) between 40 and 50 mg of each stabilizer per 100 ml of the solution from step (b) and continue stirring for a time interval between 1-3 hours, preferably 2 hours and
    [0082] (d) sonicate the solution in an ultrasound bath at 4-8 ° C at an intensity between 180 and 220 W and ambient pressure for 0.5-2 hours, preferably 1 hour.
    [0084] The process optionally comprises the extraction of the solvent used by evaporation.
    [0086] Some type of inorganic solvent such as water, or some type of organic solvent such as dimethylsulfoxide (DMSO) or a mixture of both, can be used as solvents of the composition in micrometer size.
    [0088] The aqueous solvent can be water, more preferably milliQ grade water of resistivity 18.2 MQ.cm.
    [0090] Stirring in the stages of the synthesis process can be carried out in a range comprised between 250 and 300 revolutions per minute.
    [0092] The temperature of the synthesis process is between 1 ° C and 45 ° C, preferably between 4 ° C and 25 ° C.
    [0094] Another additional aspect of the present invention refers to a composition in micrometer size for use in enhancing the action of pharmacologically active plant alkaloids.
    [0095] Said use comprises the following stages:
    [0097] (a) administering a pharmacologically active plant alkaloid, or a precursor thereof, to a living being,
    [0099] (b) administering the composition of the invention to the living being.
    [0101] Steps (a) and (b) can be carried out in any order, simultaneously without previously mixing the alkaloid and the composition, or by mixing them.
    [0103] In a preferred embodiment, the living being is a human being.
    [0105] When the micron-sized composition and the pharmacologically active plant alkaloid are co-administered to patients or living beings, there is usually a pathological process or cell group with abnormal behavior. This pathological process can comprise, for example, an uncontrolled growth of a group of cells or a cellular dysfunction due to the alteration of some metabolic process.
    [0107] The composition in micrometer size dissolves in the biological fluids present in the living being, allowing a homogeneous distribution in said medium and the controlled release of metal ions by the body. In this way, the concentration of these metal ions in the living being remains constant for a longer period, covering practically the entire period of action of the co-administered pharmacologically active plant alkaloid, thus enhancing its effect. Thus, high concentrations of the composition in micrometer size at the time of inoculation and a rapid decrease in the concentration of the administered substances are avoided.
    [0109] The final concentration of the composition in micrometer size, in the biological fluids of the patient, can be between 0.5 and 50 pg / ml.
    [0111] As previously mentioned, the composition of metal oxides, polymers and stabilizers produces a controlled release of metal oxides, reducing fluctuations in the concentration of the active material and its consequent toxicity. On the other hand, the metal oxides used in the present invention are not toxic since they are administered at low doses thanks to the fact that this presentation in the form of polymeric molecules allows a repeated supply, which favors pharmacological treatment.
    [0112] The composition of the present invention can be administered in both solid and liquid form.
    [0114] Administration can be done continuously (as a constant inflow) or semi-continuously (periodically),
    [0116] Administration can preferably be carried out topically or parenterally.
    [0118] However, this administration can be carried out with any of the methods that can be used for the administration of the co-administered biologically active plant alkaloid.
    [0120] The pharmacological treatment can be carried out continuously, periodically administering to the living being the pharmacologically active plant alkaloid and the composition to which the present invention refers.
    [0122] The pharmacologically active plant alkaloids are soluble in some type of organic or inorganic solvent. Preferably, suspension of the plant alkaloids in aqueous solvents is preferred.
    [0124] The micrometer-sized composition can be used as an adjuvant agent to enhance the effect of various pharmacologically active plant alkaloids, for example: docetaxel, paclitaxel or cabazitaxel, or a precursor thereof.
    [0126] The composition to which the present invention refers can be used as an adjuvant agent to treat different pathologies, among which the neoplasms selected from among: breast, stomach, lung and prostate, preferably prostate, stand out.
    [0128] To demonstrate the efficacy of the invention, a plant alkaloid has been used whose final effect is cell death through various mechanisms, for which we have used a technique for measuring apoptotic processes (Caspase 3 activity), a technique for measuring cell viability and mitochondrial activity (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide reduction assay, MTT) and another technique to measure the effect of the composition of the invention on the tumor cell death (Lactate Dehydrogenase, LDH enzyme assay).
    [0129] Brief description of the figures
    [0131] Figure 1. Particle size distribution by laser diffraction after preparing a suspension of the 1% composition in distilled water.
    [0133] Figure 2. Assessment of cell death by LDH assay. Percentages of LDH released to the culture medium by human prostate cancer LnCaP cells, after incubating them at different times with the composition referred to in the present invention (50 pg / ml). The data are expressed as mean ± sem (n = 6). The data in each column indicate the percentage of cell death that occurs after each corresponding treatment. Controls correspond to cells not exposed to the product (exposure time = 0).
    [0135] Figure 3. LDH assay after 72 hours of exposure. The human prostate cancer LnCaP cells were incubated with different concentrations (pg / ml) of the composition to which the present invention refers. The data are expressed as mean ± sem (n = 6). The data in each column indicate the percentage of cell death that occurs after each corresponding treatment. Controls correspond to cells treated with milliQ quality water as a vehicle.
    [0137] Figure 4.- Evaluation of the toxicity of the vegetal alkaloid docetaxel by means of the LDH test. Percentages of LDH released to the culture medium by human prostate cancer LnCaP cells, after incubating them at different times with docetaxel (10 nM). The data are expressed as mean ± sem (n = 6). * p <0.05, ** p <0.01, compared to control cells (exposure time = 0). The data in each column indicate the percentage of cell death that occurs after each corresponding treatment.
    [0139] Figure 5.- Study of the effect of the co-administration of the composition referred to in the present invention on the cell death induced by docetaxel (10 nM, 72h). The mortality of human prostate cancer LnCaP cells is expressed as a function of the percentage of LDH released. The data are expressed as mean ± sem (n = 6). * p <0.05, with respect to cells treated only with docetaxel. The data in each column indicate the percentage of cell death that occurs after each corresponding treatment.
    [0141] Figure 6. Evaluation of cytotoxicity by the MTT assay. Percentages of MTT transformed into formazan with respect to the control group (treated with milliQ quality water as a vehicle), by human prostate cancer LnCaP cells, after incubating them at different times with the composition to which the present invention refers (50 pg / ml). The data are expressed as mean ± sem (n = 6). The data in each column indicate the percentage of cell viability or mitochondrial activity with respect to the control (exposure time = 0), which is considered to be 100% viability.
    [0143] Figure 7. MTT test after 72 hours of exposure. The human prostate cancer LnCaP cells were incubated with different concentrations (pg / ml) of the composition to which the present invention refers. The data are expressed as mean ± sem (n = 6). The data in each column indicate the percentage of cell viability or mitochondrial activity with respect to the control (treated with milliQ quality water as a vehicle), which is considered to have a viability of 100%.
    [0145] Figure 8. Evaluation of the toxicity of the vegetal alkaloid docetaxel by means of the MTT test. Percentages of MTT transformed into formazan with respect to the control group (exposure time = 0) by human prostate cancer LnCaP cells, after incubating them at different times with docetaxel (10 nM). The data are expressed as mean ± sem (n = 6). * p <0.05, ** p <0.01, compared to control cells. The data in each column indicate the percentage of cell viability or mitochondrial activity with respect to the control, which is considered to be 100% viability.
    [0147] Figure 9. Study of the effect of the co-administration of the composition referred to in the present invention on cell viability after treatment with the plant alkaloid docetaxel (10 nM, 24h). The viability of human prostate cancer LnCaP cells is expressed as a function of the percentage of MTT transformed into formazan with respect to the control group (treated with milliQ quality water as a vehicle). The data are expressed as mean ± sem (n = 6). * p <0.05, ** p <0.01, with respect to cells treated only with the plant alkaloid docetaxel.
    [0149] Figure 10. Study of the activation of caspase 3 after treatments with the vegetal alkaloid docetaxel (10nM) and after treatment with the vegetal alkaloid docetaxel (10nM) the composition to which the present invention refers (50pg / ml) in cultures of human prostate cancer LnCaP cells. Controls correspond to cells treated with milliQ quality water as a vehicle. Data are expressed as mean ± sem (n = 6). * p <0.05, compared to the control.
    [0150] Realization examples
    [0152] Hereinafter, some exemplary embodiments are presented with an illustrative and non-limiting character in order to complete the description and to help a better understanding of the characteristics of the invention.
    [0154] Preparation of the composition in micrometer size
    [0156] To prepare the composition referred to in the present invention in aqueous phase, using milli-Q quality water, quantities of 40-50 g of each of the following compounds: magnesium oxide (MgO), selenium dioxide (SeO 2 ), iron (II) oxide (FeO), molybdenum trioxide (MoO3), zinc oxide (ZnO) and aluminum oxide (ALO3); they were dissolved in 1 liter of water. After 30 min of vigorous stirring (between 250-300 RPM), 3-4 g of cellulose acetate were added and vigorous stirring continued for another 30 minutes. Then 400-500 mg of PEG was added and vigorous stirring was continued for a further 2 hours. Finally, the solution was sonicated in a 200W power ultrasound bath (Selecta) with ice water (4-8 ° C) and ambient pressure, for 1 hour.
    [0158] Figure 1 shows the size of the compositions in micrometer size, measured by laser beam diffraction (Mastersizer 3000, Malvern Instruments). This measurement was carried out several times and after repeated synthesis procedures, similar results were obtained, which shows that it is a stable and reproducible process.
    [0160] Cell line cultures
    [0162] LnCaP cells (ATCC® CRL-1740 ™) are a well characterized human Prostate Carcinoma cell line. They were cultured in RPMI-1640 medium with 10% FBS, 2mM glutamine, and antibiotics (penicillin 100 Ul / ml and streptomycin 100 pg / ml), according to the manual of the cell line origin bank and previous publications (Alonso V et al., Life Sci. 2009; 85: 421-30).
    [0164] Cytotoxicity Studies. Determination of the enzyme lactate dehydrogenase (LDH).
    [0166] These tests to evaluate the toxicity of the micrometer-sized compositions were carried out in the culture of LnCaP tumor cells, determining the activity of the enzyme lactate dehydrogenase (LDH) (Posadas I et al., Pharm Res. 2009; 26: 1181-91). Figures 2, 3, 4 and 5 complete this description of the cytotoxicity studies.
    [0168] For this, the cells were seeded in 24-well plates and exposed to solutions with different concentrations of the polymeric material to which the present invention refers and of the pharmacologically active plant alkaloid to perform concentration-dependent and time-dependent toxicity curves.
    [0170] The toxic effects were evaluated by measuring the rupture of the cell membrane and the consequent release of LDH to the supernatant through the CytoTox96® kit (Promega) and the results can be seen in the graphs.
    [0172] The cells were mechanically detached, washed with PBS, and centrifuged at 10,000 rpm for 10 minutes.
    [0174] The absorbance of the lysate and the cell supernatant was measured using a microplate spectrophotometer at a wavelength of 490nm.
    [0176] The results obtained with this technique used to evaluate cell death show that our composition in micrometric size, at the doses and times studied, is not toxic for this type of LnCaP cells of prostate cancer (Figs. 2 and 3). On the contrary, docetaxel (10 nM) does produce a significant cytotoxic effect after exposing the cells for 48 and 72 hours (Fig. 4). This effect after 72 hours of exposure is significantly increased when the plant alkaloid docetaxel (10 nM) and the composition described in the present invention are co-administered at doses of 10 and 50 gg / ml, compared to the administration of the plant alkaloid alone ( Fig. 5).
    [0178] The results show that when the composition in micrometer size is co-administered together with a pharmacologically active plant alkaloid, the cytotoxic effect is significantly greater than when the plant alkaloid is administered alone.
    [0180] Cytotoxicity Studies. 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium (MTT) bromide reduction assay.
    [0182] This test is a quantitative colorimetric method that is based on the reduction of MTT, or tetrazolium salt, by the action of mitochondrial succinate dehydrogenase, generating crystals of formazan that are insoluble in aqueous medium, but solubilizable through the use of organic solvents. This product can be quantified spectrophotometrically.
    [0183] To measure mitochondrial activity (marker of cell functionality and viability), 200 µl of a solution with MTT substrate (Sigma) at a concentration of 5 mg / ml was added to the cells. After a 4 hour incubation, the supernatant was removed and the insoluble formazan crystals formed were dissolved in 200 µl of DMSO. The absorbance was measured in a spectrophotometer at an A of 540 nm, also using a reference A of 690 nm. Cell viability (mitochondrial activity) was expressed as a percentage of MTT transformed into formazan with respect to the control group treated with vehicle (milliQ quality water) (Posadas I et al. Br J Pharmacol. 2007; 150: 577-85).
    [0185] The results obtained with this technique used to evaluate cell viability, show that the composition of micrometric size referred to in the present invention at the doses and times studied, are not toxic for this type of LnCaP cells of prostate cancer (Figs. 6 and 7). On the contrary, docetaxel (10 nM) does significantly reduce cell viability after exposing the cells for a time equal to or greater than 24 hours (Fig. 8). This effect after 24 hours of exposure is significantly increased when the vegetal alkaloid docetaxel (10nM) and the composition described in the present invention are co-administered at doses equal to or greater than 0.5 pg / ml, compared to the administration of the vegetal alkaloid in solitary (Fig. 9).
    [0187] The results show that when our composition in micrometer size is co-administered with a plant alkaloid, the cytotoxic effect is significantly greater than when the plant alkaloid is administered alone.
    [0189] Apoptosis study. Determination of caspase 3 activity.
    [0191] Caspases are proteins capable of hydrolyzing other proteins at specific sites. Taking advantage of this characteristic, caspase 3 activity, which participates in the final phases of the apoptosis process), can be quantified thanks to the design of peptide sequences, specifically recognized as a substrate, to which a fluorophore or chromophore that is activated by the be separated by the specific hydrolysis exerted by this enzyme.
    [0193] The fluorogenic substrate Z-DEVD-AFC (Calbiochem) was used, which is recognized by caspase 3, since it contains the recognition sequence Asp-Glu-Val-Asp (DEVD), and is bound to the 7-amino-4 fluorophore. -trifluoromethyl coumarin (AFC), which fluoresces when the peptide is hydrolyzed. The intensity of fluorescence generated by the activated fluorophore is directly proportional to the caspase 3 activity present in the LnCaP cells used.
    [0194] Following the usual protocol in the area, after the corresponding treatments, the cells were washed with PBS and detached by trypsinization. The pellet resulting from centrifugation at 1200 rpm (150 xg), 5 minutes at 4 ° C, was resuspended in a lysis buffer (in mM: 100 HEPES, 5 DTT, 5 EGTA, 0.04% Nonidet P-40 and 20% glycerol, with a pH 7.4) and incubated for 60 minutes at 4 ° C, after which the samples were centrifuged at 4200 rpm (1800 xg) for 15 minutes at 4 ° C. The protein concentration in the supernatants was determined by the Bradford method, following a standard protocol (Jordan J et al. J Neurochem.
    [0195] 2004; 89: 124-33).
    [0197] Cell extracts (30 pg protein) were incubated with a reaction buffer (in mM: 25 HEPES, 10 DTT, 10% sucrose and 0.1% 3 - [(3-cholamido propyl) -dimethylammonium] -2 acid -hydroxy-1-propanesulfonic) containing 50 pM of fluorescent substrate Z-DEVD-AFC, at 37 ° C for 1 hour. The emitted fluorescence was determined in a spectrophotometer at an excitation A of 400 nm and an emission A of 505 nm (Jordan J et al. J Neurochem.
    [0198] 2004; 89: 124-33).
    [0200] The results obtained with this technique used to evaluate the involvement of apoptotic or programmed cell death processes show that this type of process is present in the cytotoxicity produced by the plant alkaloid docetaxel at doses of 10 nM for 24 hours. This apoptotic pathway is significantly increased when the plant alkaloid docetaxel (10 nM) and the composition in micrometer size described in the present invention are co-administered at doses of 50 pg / ml, compared to the administration of the plant alkaloid alone (Fig. 10 ).
    [0202] Data collection and analysis.
    [0204] Each value obtained corresponds to a minimum of 6 experiments (n = 6). All data are presented as mean ± s.e.m. The differences between the groups, for each of the parameters analyzed, were analyzed with a non-parametric ANOVA test (Kruskal-Wallis), followed by an ad-hoc test (Dunnett). A p less than or equal to 0.05 was considered significant. SPSS 13.0 software (Chicago, IL) was used to perform all statistical analysis.
    权利要求:
    Claims (20)
    [1]
    1 A composition in micrometer size, comprising:
    - at least one metal oxide,
    - at least one natural or synthetic polymer, or a combination of both, and
    - at least one stabilizer.
    [2]
    2. - Composition according to claim 1, in which the metal oxide is selected from oxide of: magnesium, iron, molybdenum, zinc, aluminum, selenium and a mixture thereof.
    [3]
    3. - Composition according to claim 1, in which the polymer is selected from: cellulose, agarose, polystyrene, polyvinyl alcohol (PVOH), and polyvinylidene fluoride (PVDF).
    [4]
    4. - Composition according to claim 1, in which the stabilizer is selected from polyethylene glycol (PEG), polyethyleneimine (PEI), polyacrylic acid and isopropylacrylamine, preferably polyethylene glycol.
    [5]
    5. - Composition according to any one of the preceding claims, in which the metal oxide is present in the form of microparticles of diameter between 1 pm and 10 pm.
    [6]
    6. - Composition according to the preceding claim, in which the dimensions of the composition particles are between 1-100 pm, both sizes included.
    [7]
    7. - Composition according to the preceding claim, in which the composition in micrometer size comprises a mixture of metal oxides, cellulose and polyethylene glycol (PEG), the metal oxides are magnesium oxide (MgO), selenium dioxide (SeO 2 ), iron (II) oxide (FeO), molybdenum trioxide (MoOs), zinc oxide (ZnO) and aluminum oxide (M 2 O 3 ).
    [8]
    8. - Process for the synthesis of the composition defined in one of claims 1 to 7, comprising the following steps:
    (a) dissolve at least one metal oxide in a solvent to achieve a concentration of 4 5 g of each oxide per 100 ml of the solvent,
    (b) add to the solution from step (a) between 300 and 400 mg of each polymer for every 100 ml of the solution from step (a),
    (c) add to the solution from step (b) between 40 and 50 mg of each stabilizer for every 100 ml of the solution from step (b) and
    (d) sonicate the solution (c).
    [9]
    9. - Process according to the preceding claim, which further comprises, after step (d) extracting the solvent used by evaporation.
    [10]
    10. - Process according to any one of claims 8 to 9, in which an organic, inorganic solvent or a mixture of both is used as the solvent of the composition.
    [11]
    11. Synthesis process according to the preceding claim, in which the temperature of any of steps (a) (b) and (c) is between 1 ° C and 45 ° C, preferably between 4 ° C and 25 ° C.
    [12]
    12. Composition in micrometric size defined in one of claims 1 to 7, for use in enhancing the action of pharmacologically active plant alkaloids.
    [13]
    13. Composition according to the preceding claim, in which the use comprises the following steps:
    (a) administer a pharmacologically active plant alkaloid, or a precursor thereof, to the living being and
    (b) administering the composition of the invention to the living being.
    [14]
    14. Composition according to the preceding claim, in which steps (a) and (b) are carried out in any order, or simultaneously without previously mixing the alkaloid and the composition, or mixing them.
    [15]
    15. Composition according to any one of claims 12 to 14, in which the living being is a human being.
    [16]
    16. Composition according to any one of claims 12 to 15, in which the composition in micrometer size is administered both in solid and liquid form.
    [17]
    17. Composition according to any one of claims 12 to 16, in which the administration is carried out:
    - continuously, constant inflow or
    - semi-continuously, periodically.
    [18]
    18. Composition according to the preceding claim, in which the administration is carried out topically or parenterally.
    [19]
    19. - Composition according to any one of claims 12 to 18, in which the composition in micrometric size is used as an adjuvant agent to enhance the effect of pharmacologically active plant alkaloids, selected from: docetaxel, paclitaxel, cabazitaxel, and a precursor of said alkaloids.
    [20]
    20. - Composition according to any one of claims 12 to 19, in which the composition in micrometric size is used as an adjunct agent to treat pathologies selected from breast, stomach, lung and prostate neoplasms, preferably prostate.
    类似技术:
    公开号 | 公开日 | 专利标题
    Feng et al.2018|Hypoxia-specific therapeutic agents delivery nanotheranostics: A sequential strategy for ultrasound mediated on-demand tritherapies and imaging of cancer
    Li et al.2012|Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes
    Long et al.2013|Induction of apoptosis and inhibition of angiogenesis by PEGylated liposomal quercetin in both cisplatin-sensitive and cisplatin-resistant ovarian cancers
    Dragicevic-Curic et al.2008|Topical application of temoporfin-loaded invasomes for photodynamic therapy of subcutaneously implanted tumours in mice: a pilot study
    Mroz et al.2011|Intraperitoneal photodynamic therapy mediated by a fullerene in a mouse model of abdominal dissemination of colon adenocarcinoma
    Zhang et al.2019|Interventional photothermal therapy enhanced brachytherapy: A new strategy to fight deep pancreatic cancer
    Park et al.2016|Gold-conjugated resveratrol nanoparticles attenuate the invasion and MMP-9 and COX-2 expression in breast cancer cells
    Lin et al.2017|“In vivo self-assembled” nanoprobes for optimizing autophagy-mediated chemotherapy
    You et al.2018|Porphyrin-grafted lipid microbubbles for the enhanced efficacy of photodynamic therapy in prostate cancer through ultrasound-controlled in situ accumulation
    US20100262115A1|2010-10-14|Nanoparticles for cancer sonodynamic and photodynamic therapy
    ES2853973T3|2021-09-20|Use of DNQ or DNQ-87 in combination with a PARP1 inhibitor for the treatment of cancer
    BR112020025760A2|2021-03-16|USE OF ALTERNATE ELECTRIC FIELDS TO INCREASE THE PERMEABILITY OF THE CELLULAR MEMBRANE
    Shao et al.2019|Auto-fluorescent polymer nanotheranostics for self-monitoring of cancer therapy via triple-collaborative strategy
    Moussa et al.2014|Nanodrug-enhanced radiofrequency tumor ablation: effect of micellar or liposomal carrier on drug delivery and treatment efficacy
    Chen et al.2017|NIR responsive liposomal system for rapid release of drugs in cancer therapy
    Meng et al.2019|Oxygen-rich chemotherapy via modified Abraxane to inhibit the growth and metastasis of triple-negative breast cancer
    Wang et al.2019|Delivery of folic acid-modified liposomal curcumin for targeted cervical carcinoma therapy
    Chang et al.2021|Porphyrin-lipid stabilized paclitaxel nanoemulsion for combined photodynamic therapy and chemotherapy
    Huang et al.2020|The potential of lonidamine in combination with chemotherapy and physical therapy in cancer treatment
    US6602910B2|2003-08-05|D-enantiomer of DFMO and methods of use therefor
    Xu et al.2021|Ferroptosis/pyroptosis dual-inductive combinational anti-cancer therapy achieved by transferrin decorated nanoMOF
    ES2823927B2|2022-01-18|Composition in micrometric size and its use as an adjuvant agent of vegetable alkaloids
    Castañeda-Gill et al.2017|Development and characterization of methylene blue oleate salt-loaded polymeric nanoparticles and their potential application as a treatment for glioblastoma
    Wang et al.2020|Salinomycin nanocrystals for colorectal cancer treatment through inhibition of Wnt/β-catenin signaling
    Ahmed et al.2020|Development and characterization of Brigatinib loaded solid lipid nanoparticles: In-vitro cytotoxicity against human carcinoma A549 lung cell lines
    同族专利:
    公开号 | 公开日
    WO2021089278A1|2021-05-14|
    ES2823927B2|2022-01-18|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    WO1997007675A1|1995-08-31|1997-03-06|Allied Colloids Limited|Products and processes for the sustained release of agricultural active ingredients|
    EP2896398A1|2012-09-12|2015-07-22|University of Tsukuba|Surface-modified iron oxide particles for cancer cauterization|
    ES2624730A1|2015-12-16|2017-07-17|Enersos I, S.L.|Polymer metallic particles for the production of biogas |
    CN109276561A|2018-11-12|2019-01-29|浙江诚缘生物科技有限公司|A kind of nano zine oxide enteric-coated micro-pill and preparation method thereof|
    CA2833413C|2011-04-20|2020-09-22|The University Of Sydney|A method for the treatment of a solid tumour|
    WO2013101810A1|2011-12-27|2013-07-04|Celgene Corporation|Formulations of -2-[1--2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione|
    US20150174549A1|2013-10-25|2015-06-25|The Brigham And Women's Hospital Corporation|High-throughput synthesis of nanoparticles|
    法律状态:
    2021-05-10| BA2A| Patent application published|Ref document number: 2823927 Country of ref document: ES Kind code of ref document: A1 Effective date: 20210510 |
    2022-01-18| FG2A| Definitive protection|Ref document number: 2823927 Country of ref document: ES Kind code of ref document: B2 Effective date: 20220118 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201930977A|ES2823927B2|2019-11-07|2019-11-07|Composition in micrometric size and its use as an adjuvant agent of vegetable alkaloids|ES201930977A| ES2823927B2|2019-11-07|2019-11-07|Composition in micrometric size and its use as an adjuvant agent of vegetable alkaloids|
    PCT/EP2020/078694| WO2021089278A1|2019-11-07|2020-10-13|Micrometric size composition and its use as a plant alkaloid coadjuvant agent|
    [返回顶部]